Nolan J. Maloney

Nolan J. Maloney

Auto-generated profile, based on publicly available information

Nolan J. Maloney

Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
NMNolan J. Maloney
Nolan J. Maloney
VRVignesh Ravi
Vignesh Ravi
KCKyle Cheng
Kyle Cheng
DBDaniel Q. Bach
Daniel Q. Bach
SWScott Worswick
Scott Worswick

21 September 2020 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JYJason J. Yang
Jason J. Yang
DLDonald K. Lei
Donald K. Lei
VRVignesh Ravi
Vignesh Ravi
NMNolan J. Maloney
Nolan J. Maloney
ACAshley Crew
Ashley Crew
SWScott Worswick
Scott Worswick

3 October 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
KTKyle Tegtmeyer
Kyle Tegtmeyer
JZJeffrey Zhao
Jeffrey Zhao
NMNolan J. Maloney
Nolan J. Maloney
GAGiancarlo Atassi
Giancarlo Atassi
MBMolly Beestrum
Molly Beestrum
PLPeter Lio
Peter Lio
Purpose: Tofacitinib citrate is an oral Janus kinase 1/3 inhibitor approved for rheumatoid arthritis, ulcerative colitis, and active psoriatic arthritis. Tofacitinib is being increasingly used off-label for dermatological conditions, with varying efficacy across recent studies. A review of these studies will be a helpful resource for dermatologists considering the use of tofacitinib for conditions refractory to first-line therapies. Materials and methods: MEDLINE, Embase, CINAHL Plus, Cochrane Library, Scopus, Web of Science, Clinicaltrials.gov, and the WHO International Clinical Trials Registry Platform were all searched for articles and trials mentioning the term ‘tofacitinib’, then manually reviewed to identify published data on off-label uses of tofacitinib. The article was structured according to the quality of the evidence available. Results: Tofacitinib appears to show strong efficacy for numerous dermatologic conditions. Randomized controlled trial data is available for atopic dermatitis, alopecia areata, and plaque psoriasis. Case report and case series data is available for numerous other dermatologic conditions. Conclusion: While tofacitinib has a wide array of immunoregulatory properties, making it a possible candidate for treating many dermatologic conditions refractory to other treatments, further testing is needed to better characterize its efficacy and utility moving forward, as well as its safety and adverse effect profile.

2 April 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
NMNolan J. Maloney
Nolan J. Maloney
JZJeffrey Zhao
Jeffrey Zhao
KTKyle Tegtmeyer
Kyle Tegtmeyer
ELErnest Y. Lee
Ernest Y. Lee
KCKyle Cheng
Kyle Cheng
Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. Materials and methods: The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term ‘apremilast,’ with results manually screened to identify published data on off-label uses of apremilast. The article was structured by the quality of evidence available. Results: Apremilast use in dermatology beyond plaque psoriasis and psoriatic arthritis is frequently described in the literature, with a mixture of positive and negative results. Randomized controlled data is available for Behçet’s disease, hidradenitis suppurativa, nail/scalp/palmoplantar psoriasis, alopecia areata, and atopic dermatitis. Conclusion: The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.

7 August 2019 in Dermatologic Therapy
Verified
Journal Article
Closed access
VRVignesh Ravi
Vignesh Ravi
NMNolan J. Maloney
Nolan J. Maloney
SWScott Worswick
Scott Worswick

16 August 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
LALayal Antoury
Layal Antoury
NMNolan J. Maloney
Nolan J. Maloney
DBDaniel Q. Bach
Daniel Q. Bach
CGCarolyn Goh
Carolyn Goh
KCKyle Cheng
Kyle Cheng